Showing results (11-20 of 128) with videos related to
Sort By:
Pageof 13
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|December 13, 2021
Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum DisorderDubravka Dodig, Angela Genge, Daniel Selchen, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 11, 2024
How to break the news in amyotrophic lateral sclerosis/motor neuron disease: practical guidelines from expertsColleen O'Connell, Melinda S Kavanaugh, Cathy Cummings, et al.Journal of Neurology|April 13, 2006
Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imagingSanjay Kalra, Peter Tai, Angela Genge, et al.Muscle & Nerve|February 7, 2026
Current and Ongoing Clinical StudiesAgessandro Abrahao, Lorne Zinman, Stephen AppleAmyotrophic Lateral Sclerosis & Frontotemporal Degeneration|November 8, 2024
How the prospect of a clinical trial impacts decision-making for predictive genetic testing in ALSMyriam Fontaine, Kayla Horowitz, Nancy Anoja, et al.Muscle & Nerve|February 7, 2026
Study 19 (MCI186-19) Post Hoc AnalysesBenjamin Rix Brooks, Jeremy Shefner, Stephen AppleMuscle & Nerve|December 12, 2022
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatmentAngela Genge, Gary L Pattee, Gen Sobue, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 25, 2026
Opportunities and challenges related to participant stratification and cohort enrichment in ALS clinical trialsSabrina Yusuf, Matti D Allen, HyungMo Kang, et al.Muscle & Nerve|June 6, 2025
Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02)Jeffrey Rothstein, Angela Genge, Shari De Silva, et al.Pageof 13